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Abstract
Inositol 1,4,5-trisphosphate receptors (IP3R) are intracellular Ca
2+ channels. Most animal cells express mixtures of the three
IP3R subtypes encoded by vertebrate genomes. Adenophostin A (AdA) is the most potent naturally occurring agonist of IP3R
and it shares with IP3 the essential features of all IP3R agonists, namely structures equivalent to the 4,5-bisphosphate and 6-
hydroxyl of IP3. The two essential phosphate groups contribute to closure of the clam-like IP3-binding core (IBC), and
thereby IP3R activation, by binding to each of its sides (the a- and b-domains). Regulation of the three subtypes of IP3R by
AdA and its analogues has not been examined in cells expressing defined homogenous populations of IP3R. We measured
Ca2+ release evoked by synthetic adenophostin A (AdA) and its analogues in permeabilized DT40 cells devoid of native IP3R
and stably expressing single subtypes of mammalian IP3R. The determinants of high-affinity binding of AdA and its
analogues were indistinguishable for each IP3R subtype. The results are consistent with a cation-p interaction between the
adenine of AdA and a conserved arginine within the IBC a-domain contributing to closure of the IBC. The two
complementary contacts between AdA and the a-domain (cation-p interaction and 30-phosphate) allow activation of IP3R
by an analogue of AdA (30-dephospho-AdA) that lacks a phosphate group equivalent to the essential 5-phosphate of IP3.
These data provide the first structure-activity analyses of key AdA analogues using homogenous populations of all
mammalian IP3R subtypes. They demonstrate that differences in the Ca
2+ signals evoked by AdA analogues are unlikely to
be due to selective regulation of IP3R subtypes.
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Introduction
Inositol 1,4,5-trisphosphate receptors (IP3R) are intracellular
Ca2+ channels that are expressed in almost all animal cells. They
allow release of Ca2+ from intracellular stores in response to the
many stimuli that activate phospholipase C [1,2]. The genomes of
vertebrates encode three closely related IP3R subtypes (IP3R1-3),
and most cells from vertebrates express functional IP3R that are
homo- or hetero-tetrameric assemblies of these IP3R subtypes and
their splice variants [3]. The physiological significance of this IP3R
diversity is poorly understood, and nor are there ligands that
usefully discriminate between IP3R subtypes. It is, however, clear
that activation of IP3R is initiated by binding of IP3 to the
conserved IP3-binding core (IBC, residues 224-604 of IP3R1) of
each IP3R subunit [4]. Mixed populations of IP3R in native cells
make it difficult to define unambiguously the functional properties
of each IP3R subtype. Stable heterologous expression of mamma-
lian IP3R in the only vertebrate cell line engineered to lack all
endogenous IP3R (DT40 KO cells) [5] provides an effective means
of addressing this difficulty [6]. We previously used DT40 cells
expressing homogeneous populations of each mammalian IP3R
subtype to define structure-activity relationships for key endoge-
nous and synthetic inositol phosphates [7]. Here, we extend the
approach to examine the interactions of each IP3R subtype with
adenophostin A (1, AdA) and its most important analogues [8]
(Figure 1A).
AdA, originally isolated from Penicillium brevicompactum [9,10]
and later synthesized [11], is a potent agonist of IP3R. It is also
resistant to degradation by the enzymes that degrade IP3 via
phosphorylation or dephosphorylation [10]. Although AdA is
based on a glucose ring, rather than the inositol ring of IP3, its
structure retains the key functional groups of IP3 that are known to
be essential for IP3 activity at IP3R [12] (Figure 1A). Considerable
evidence supports the original suggestion [10] that the essential
4,5-bisphosphate and 6-hydroxyl of IP3 are effectively mimicked
by the 40,30-bisphosphate and 20-hydroxyl of AdA (red highlights
in Figure 1A). The interactions that allow AdA to bind to IP3R
with about 10-fold greater affinity than IP3 have been more
difficult to resolve. One view was that the 29-phosphate of AdA is
equivalent to the 1-phosphate of IP3 and, like the latter [13] (blue
in Figure 1A), contributes to high-affinity binding to the IBC. The
suggestion was that the 29-phosphate of AdA forms a stronger
interaction with the IBC than does the 1-phosphate of IP3. Our
recent analyses have challenged this idea and instead suggest that a
cation-p interaction between the adenine ring of AdA and a
guanidinium side chain of an arginine residue within the a-domain
of the IBC (R504 in IP3R1) may be a more important determinant
of the increased affinity of AdA for IP3R [12].
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The high-affinity and metabolic stability of AdA have generated
considerable interest in both the synthesis of AdA analogues and
their application to analyses of IP3R activation and associated
changes in cytosolic Ca2+ signalling [12]. There has, however,
been no systematic analysis of the activities of AdA or its analogues
with defined populations of homogenous IP3R subtypes. The need
for such analyses is particularly important in attempting to explain
results in which Ca2+ signals evoked by IP3 differ from those
evoked by AdA [14,15,16,17,18,19,20,21], or where different
analogues of AdA evoke different cellular responses [reviewed in
12,22]. Here we use DT40 cells in which all endogenous IP3R
have been genetically inactivated [5] to stably express homogenous
populations of mammalian IP3R subtypes and thereby define
structure-activity relationships for AdA and its key analogues for
each IP3R subtype.
Materials and Methods
Materials
Sources of most reagents were provided in a previous
publication [7]. The structures of the ligands used and their
abbreviations are shown in Figure 1A. IP3 was from Alexis
Biochemicals (Nottingham, UK). AdA [23], imidophostin [24],
ribophostin [25], furanophostin [26], manno-AdA and xylo-AdA
[27], 30-dephospho AdA and 40-dephospho AdA [28], and 29-
dephospho AdA were synthesized, purified and characterized as
previously described.
Measurement Ca2+ Release by IP3 Receptors
From quantitative analyses of western blots using antisera that
selectively recognise each IP3R subtype or react equally with all
three subtypes, we established that in the DT40 cells used, levels of
IP3R expression (relative to IP3R3) were IP3R1 (7168%, n=3),
IP3R2 (4865%) and IP3R3 (100%) [7]. It is impracticable to
achieve identical levels of IP3R expression for each cell line, and
differences (albeit modest in our cell lines) may affect both the size
of the IP3-sensitive Ca
2+ pool and its sensitivity to IP3 [29]. The
different levels of IP3R expression do not compromise the analyses
reported here, which are entirely concerned with relative potencies
of AdA analogues for each IP3R subtype (see below).
A comprehensive description of the methods used to measure
free [Ca2+] within the endoplasmic reticulum of permeabilized
DT40 cells was provided in preceding publications [7,30]. Briefly,
the endoplasmic reticulum of DT40 cells stably expressing each of
the three mammalian IP3R subtypes was loaded with a low-affinity
Ca2+ indicator (Mag fluo-4) [30]. After permeabilization of the
plasma membrane with saponin (10 mg/mL, ,4 min, 37uC), the
permeabilized cells in cytosol-like medium (CLM) were distributed
into 96-well plates at 20uC. Addition of MgATP (1.5 mM) then
allowed active Ca2+ accumulation, which was monitored at
intervals of ,1 s using a FlexStation 3 fluorescence plate-reader
(MDS Analytical Devices). CLM had the following composition:
140 mM KCl, 20 mM NaCl, 1 mM EGTA, 20 mM Pipes, pH 7,
free [Ca2+] ,220 nM (after addition of MgATP), and carbonyl
cyanide 4-trifluoromethoxy-phenyl hydrazone (FCCP, 10 mM) to
inhibit mitochondrial Ca2+ uptake. After 150 s, when the stores
had loaded to steady-state with Ca2+, IP3, AdA or its analogues
was added with thapsigargin (1 mM) to prevent further Ca2+
uptake, and after a further 30 s, the response was recorded.
Agonist-evoked Ca2+ release was expressed as a fraction of that
released by ionomycin (1 mM) [30]. All experiments were
performed at 20uC.
Statistical Analysis
Concentration-effect relationships were fitted to Hill equations
using GraphPad Prism (version 5.0) from which Hill coefficients
(h), the fraction of the intracellular Ca2+ stores released by
maximally effective concentrations of agonist, and pEC50 values (-
log EC50) were calculated. For convenience some results are
presented as EC50 values, but all statistical comparisons use pEC50
values. Within each experiment, the pEC50 for AdA was
determined to allow paired comparisons with values obtained for
each AdA analogue. These are reported as DpEC50, where:
DpEC50~pEC
AdA
50 {pEC
analogue
50
We note that Table 1 reports pooled results from experiments
collected over a considerable period, whereas DpEC50 values, like
those shown in Table 2, compare only paired values. The latter
provide the most robust means of comparing agonist potencies.
Results are expressed as means 6 SEM from n independent
experiments, with each experiment performed in triplicate.
Statistical comparisons used Student’s t-test or ANOVA
followed by Bonferroni’s post hoc test, as appropriate, with
P,0.05 considered significant. Because not all comparisons of
the relative potencies of AdA and IP3 were paired, the SEM of this
DpEC50 value was calculated from:
SEM~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n1
z
1
n2
sp
s
where, sp is the estimate of the population variance:
sp~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1{1ð Þs21z n2{1ð Þs22
n1{n2{2
s
where, s1 and s2 are the sample standard deviations, and n1 and n2
are the sample sizes [31].
Results
Quantal Ca2+ Release Evoked by AdA and IP3
The kinetics of IP3-evoked Ca
2+ release from intracellular stores
are unexpectedly complex. It is widely observed that under
conditions where Ca2+ uptake into the endoplasmic reticulum
(ER) is inhibited, submaximally effective concentrations of IP3
rapidly release only a fraction of the IP3-sensitive Ca
2+ stores [32].
Thereafter, there is either no, or a massively reduced, effect of IP3
on the rate of Ca2+ release. The mechanisms underlying this
pattern of response, known as quantal Ca2+ release [33], remain
Figure 1. Structures of the analogues of AdA used. (A) Key moieties within IP3 and AdA are highlighted in matching colours to indicate their
proposed structural equivalence. (B and C). The Ca2+ contents of the intracellular stores of populations of permeabilized DT40-IP3R1 cells are shown
after addition of ATP to allow active Ca2+ uptake, and then addition of the indicated concentrations of IP3 or AdA with thapsigargin (1 mM) to inhibit
further Ca2+ uptake. The traces, which are typical of those from all subsequent analyses, show the average response from 2 wells on a single plate.
The results demonstrate that both IP3 and AdA evoke quantal Ca
2+ release.
doi:10.1371/journal.pone.0058027.g001
IP3 Receptors and Adenophostin Analogues
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e58027
T
a
b
le
1
.
Ef
fe
ct
s
o
f
A
d
A
an
al
o
g
u
e
s
o
n
C
a2
+
re
le
as
e
b
y
su
b
ty
p
e
s
o
f
IP
3
re
ce
p
to
r.
IP
3
R
1
IP
3
R
2
IP
3
R
3
E
C
5
0
p
E
C
5
0
h
C
a
2
+ r
e
le
a
se
n
E
C
5
0
p
E
C
5
0
h
C
a
2
+ r
e
le
a
se
n
E
C
5
0
p
E
C
5
0
h
C
a
2
+ r
e
le
a
se
n
(1
,4
,5
)I
P
3
8
7
7
.0
6
6
0
.0
5
0
.9
9
6
0
.0
5
7
5
6
1
3
1
1
4
5
6
.8
4
6
0
.0
6
1
.2
9
6
0
.0
9
6
1
6
2
3
4
4
1
7
6
.3
8
6
0
.0
5
1
.2
6
6
0
.0
7
6
4
6
2
3
0
A
d
A
8
.3
8
.0
8
6
0
.0
9
1
.1
7
6
0
.0
9
7
2
6
3
1
0
1
8
.2
7
.7
4
6
0
.0
6
1
.7
9
6
0
.2
1
5
6
6
2
1
3
3
3
7
.4
8
6
0
.0
9
1
.1
3
6
0
.0
7
6
1
6
2
1
4
Im
id
o
p
h
o
st
in
3
7
7
.4
3
6
0
.2
8
1
.1
7
6
0
.2
1
7
8
6
5
3
6
8
7
.1
7
6
0
.1
4
1
.8
4
6
0
.5
0
5
9
6
3
3
1
6
6
6
.7
8
6
0
.1
6
1
.7
3
6
0
.3
9
6
7
6
7
3
R
ib
o
p
h
o
st
in
4
0
7
.4
0
6
0
.2
9
1
.3
4
6
0
.1
6
7
7
6
4
3
1
0
2
6
.9
9
6
0
.1
1
1
.6
0
6
0
.5
0
6
1
6
2
3
2
9
5
6
.5
3
6
0
.2
1
1
.4
2
6
0
.0
8
6
8
6
4
3
Fu
ra
n
o
p
h
o
st
in
5
1
7
.2
9
6
0
.2
5
0
.9
0
6
0
.1
0
7
9
6
6
3
7
6
7
.1
2
6
0
.0
1
1
.7
3
6
0
.2
0
6
0
6
3
3
4
5
7
6
.3
4
6
0
.1
8
1
.2
7
6
0
.2
1
7
1
6
3
3
M
a
n
n
o
-A
d
A
3
4
7
.4
7
6
0
.1
9
1
.3
3
6
0
.3
0
7
5
6
7
3
6
9
7
.1
6
6
0
.0
7
1
.3
3
6
0
.2
2
5
7
6
3
3
2
4
5
6
.6
1
6
0
.2
3
1
.2
3
6
0
.1
5
6
9
6
4
3
X
yl
o
-A
d
A
5
.9
8
.2
3
6
0
.1
7
1
.2
7
6
0
.2
7
7
3
6
7
3
7
.9
8
.1
0
6
0
.1
0
1
.5
2
6
0
.4
0
5
2
6
6
3
2
9
7
.5
4
6
0
.1
2
1
.5
8
6
0
.2
9
6
4
6
9
3
2
9-
d
e
p
h
o
sp
h
o
-A
d
A
2
7
5
6
.5
6
6
0
.1
3
1
.3
1
6
0
.1
5
6
6
6
7
3
5
7
5
6
.2
4
6
0
.1
0
0
.8
5
6
0
.0
7
6
3
6
2
3
6
9
2
6
.1
6
6
0
.0
3
1
.5
6
0
.2
2
5
5
6
7
4
3
0-
d
e
p
h
o
sp
h
o
-A
d
A
c
N
D
N
D
N
D
1
5
6
6
b
7
N
D
N
D
N
D
6
6
2
b
6
N
D
N
D
N
D
7
6
7
b
5
4
0-
d
e
p
h
o
sp
h
o
-A
d
A
In
ac
ti
ve
a
In
ac
ti
ve
a
In
ac
ti
ve
a
N
D
6
In
ac
ti
ve
a
In
ac
ti
ve
a
In
ac
ti
ve
a
N
D
6
In
ac
ti
ve
a
In
ac
ti
ve
a
In
ac
ti
ve
a
N
D
5
T
h
e
EC
5
0
(n
M
),
p
EC
5
0
(/
M
),
H
ill
co
e
ff
ic
ie
n
t
(h
)
an
d
fr
ac
ti
o
n
(%
)
o
f
th
e
in
tr
ac
e
llu
la
r
C
a2
+
st
o
re
s
re
le
as
e
d
b
y
a
m
ax
im
al
ly
e
ff
e
ct
iv
e
co
n
ce
n
tr
at
io
n
o
f
e
ac
h
an
al
o
g
u
e
ar
e
sh
o
w
n
fo
r
e
ac
h
IP
3
R
su
b
ty
p
e
.A
ll
re
su
lt
s
(e
xc
e
p
t
EC
5
0
)
ar
e
sh
o
w
n
as
m
e
an
s
6
SE
M
fr
o
m
n
in
d
e
p
e
n
d
e
n
t
e
xp
e
ri
m
e
n
ts
.
a
In
ac
ti
ve
at
3
0
0
mM
.
b
C
a2
+
re
le
as
e
e
vo
ke
d
b
y
3
0
0
mM
3
0-
d
e
p
h
o
sp
h
o
A
d
A
.
c
R
e
fe
r
to
T
ab
le
2
fo
r
re
la
ti
ve
p
o
te
n
ci
e
s
o
f
3
0-
d
e
p
h
o
sp
h
o
A
d
A
.
N
D
,
n
o
t
d
e
te
rm
in
e
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
5
8
0
2
7
.t
0
0
1
IP3 Receptors and Adenophostin Analogues
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e58027
unclear. It may require desensitization of IP3R as the Ca
2+ content
of the ER declines [34] or heterogeneity among IP3-senstive Ca
2+
stores [35]. The results shown in Figures 1B and C confirm that
the Ca2+ release evoked by submaximal concentrations of either
IP3 or AdA from permeabilized DT40-IP3R1 cells is quantal.
These observations provide the justification for all subsequent
experiments in which the concentration-dependent effects of IP3
or AdA were measured 30 s after their addition (see Methods).
AdA is a Potent Agonist of All Three IP3 Receptor
Subtypes
The results shown in Figure 2 and Tables 1 and 2 demonstrate
that AdA is,10-times more potent than IP3 at each IP3R subtype,
and for each subtype, maximally effective concentrations of IP3
and AdA release the same fraction of the intracellular Ca2+ stores.
This is consistent with many analyses of IP3 and AdA in a variety
of cell types using both functional and binding assays, in which
AdA behaves as a full agonist with ,10-fold greater affinity than
IP3 [reviewed in 8]. Our results do, however, provide the first
direct demonstration that AdA interacts similarly with all three
IP3R subtypes. Subsequent experiments examine the interactions
between key analogues of IP3 and AdA with each IP3R subtype.
Trimming the Adenosine Moiety of AdA Reduces its
Potency at All IP3 Receptor Subtypes
Systematic trimming of the adenosine moiety of AdA succes-
sively produces imidophostin (which lacks the pyrimidine ring of
AdA), ribophostin (in which a methoxy group replaces the adenine
moiety of AdA) and furanophostin (in which only the furanoid ring
remains) (Figure 1A). Maximally effective concentrations of each
of these analogues released the same fraction of the intracellular
Ca2+ stores as AdA in cells expressing each of the three IP3R
subtypes, and each analogue was ,5-10-fold less potent than AdA
(Figure 3, Tables 1 and 2). These results are consistent with
previous analyses of IP3R in hepatocytes, which express predom-
inantly IP3R2 [24,36], with analyses of binding of ribophostin and
furanophostin to an N-terminal fragment of IP3R1 [12], and with
evidence from other analogues that trimming the adenosine
Figure 2. AdA is a potent agonist of all three IP3 receptor
subtypes. (A) Concentration-dependent effects of AdA on Ca2+ release
from the intracellular stores of cells expressing IP3R1, IP3R2 or IP3R3. All
results are expressed as percentages of the Ca2+ release evoked by
ionomycin. The same colour codes are used in all subsequent figures.
(B) Comparison, for each IP3R subtype, of the Ca
2+ release evoked by IP3
and AdA. Results are means 6 SEM from the number of independent
experiments given in Table 1. Here, and in many subsequent figures,
some error bars are smaller than the symbols.
doi:10.1371/journal.pone.0058027.g002
Table 2. Relative potencies of AdA analogues at different IP3
receptor subtypes.
IP3R1 IP3R2 IP3R3
IP3 1.0260.02 0.960.30 1.160.30
Imidophostin 0.7860.15 0.7860.08 0.8160.04
Ribophostin 0.8260.18 0.9660.20 1.0660.07
Furanophostin 0.9260.13 0.8360.14 1.2560.05
Manno-AdA 0.7460.08 0.7960.18 0.9860.08
Xylo-AdA 20.0160.07 20.360.27 0.0560.08
29-dephospho-AdA 1.2460.33 1.6060.18 1.6860.16
30-dephospho-
AdAa
4.0360.09 4.4760.30 4.1360.14
From paired comparisons with AdA, the potency (DpEC50) of the analogues
relative to AdA is shown for each IP3R subtype. Results are means6 SEM, with n
provided in Table 1. ND, not determined. aBecause the very low affinity of 30-
dephospho AdA for IP3R made it impracticable to stimulate cells with a
maximally effective concentration, ‘DpEC50’ for 30-dephospho AdA was
estimated by comparing concentrations of it and AdA that evoked the same
sub-maximal Ca2+ release.
doi:10.1371/journal.pone.0058027.t002
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moiety decreases affinity for cerebellar IP3R, which are largely
IP3R1 [37].
These results are consistent with our earlier conclusion that the
10-fold greater affinity of AdA relative to IP3 requires the adenine
moiety of AdA positioned to allow it to form a cation-p interaction
with Arg-504 in the a-domain of the IBC of IP3R1, a residue that
is conserved in all IP3R subtypes [8,12] (Figure 3G). We suggest
that this interaction of AdA with IP3R is likely to be similar for all
IP3R subtypes.
Hydroxyl Moieties that are Important for IP3 Binding are
Less Important for Binding of AdA
The 50-CH2OH and 20-OH substituents of the glucose ring of
AdA are thought to mimic the 3-OH and 6-OH of IP3,
respectively (Figure 1A). A structure equivalent to the 6-OH of
IP3 is an essential feature of all inositol phosphate analogues that
bind to IP3R [13,38,39] and inversion of its orientation from
equatorial to axial reduces affinity by more than 100-fold at all
IP3R subtypes [40]. It is therefore surprising, but consistent with
previous analyses of native hepatic IP3R [36], that manno-AdA,
which differs from AdA only in the orientation of its 20-OH,
should be only 5- to 10-fold less potent than AdA at each IP3R
subtype (Figures 4A and B, Tables 1 and 2). Why, when the 6-OH
of IP3 and 20-OH of AdA seem to be analogous in the ligand
structures, should these moieties make such different contributions
to the interactions of IP3 and AdA with IP3R?
The 6-OH of IP3 interacts, through a water molecule, with a
lysine residue (K569) in the IBC [41] and, by interacting with the
adjacent 1-phosphate, it has also been proposed to influence the
behaviour of the 4,5-bisphosphate moiety of IP3 [42]. The latter
interaction is unlikely to contribute to AdA binding because the
structures equivalent to the 6-OH (20-OH of AdA) and the 1-
phosphate of IP3 (29-phosphate of AdA) are in different rings in
AdA (Figure 1A). We suggest that the lesser importance in AdA of
a structure equivalent to the essential 6-OH of IP3 comes from this
hydroxyl mediating a relatively minor interaction with K569 in
AdA, whereas for IP3 it contributes also to appropriately orienting
the critical 4,5-bisphosphate moiety.
The 3-OH group, although less important than the 6-OH, is
another feature of IP3 that contributes to high-affinity binding
[43]. Our recent analyses of the functional effects of 3-deoxy-IP3
established that it was ,40-fold less potent than IP3 at all three
IP3R subtypes [7]. This is consistent with earlier work showing
that 3-deoxy-IP3 and analogues with other modifications of the 3-
position have reduced affinity for the three IP3R subtypes [40].
However, the equivalent modification of AdA, removal of its 50-
CH2OH to give xylo-AdA (Figure 1A), had no significant effect on
its potency at any IP3R subtype (Figures 4C and D, Tables 1 and
2). This is consistent with a previous functional analysis of hepatic
IP3R, where xylo-AdA was only marginally less potent than AdA
(DpEC50 ,0.28) [36]. Our results suggest that despite the
apparent structural similarity between the 3-OH of IP3 and the
50-CH2OH of AdA (Figure 1A), the two hydroxyl groups do not
contribute similarly to ligand binding. Previous analyses of IP3
analogues suggested that replacing the 3-OH with the larger
CH2OH moiety caused the affinity to decrease by no more than 7-
fold [40]. A partial explanation for the lack of effect of removing
the 50-CH2OH of AdA may therefore be that this moiety is less
readily accommodated than a hydroxyl group in the IBC. This
would suggest that an analogue of AdA in which the 50-CH2OH is
replaced by 50-OH might bind with increased affinity. We are
unaware of such an analogue having been synthesized. The larger
substituent at the 50-position of AdA is, however, unlikely to
provide the sole explanation for it making no discernible
contribution to binding.
The 29-phosphate of AdA is not a Super-optimal Mimic of
the 1-phosphate of IP3
It has been suggested that the 29-phosphate of AdA interacts
with the IBC in a manner that allows it to behave as a super-
optimal mimic of the 1-phosphate of IP3 [44,45]. However, our
recent study combining structure-activity analyses with mutagen-
esis of the binding site suggest that the 1-phosphate of IP3 is more
important for binding than is the 29-phosphate of AdA [12].
Removal of the 1-phosphate from IP3 (to give (4,5)IP2) caused its
potency and affinity for IP3R1 to decrease by ,100-fold [12],
whereas removal of the 29-phosphate from AdA (29-dephospho
AdA) causes a decrease in potency of ,17-fold in IP3R1 (Figure 5)
and ,40-fold decreases in potency were obtained with 29-
dephospho AdA and IP3R2 and IP3R3 (Figure 5, Table 1 and
2). These results establish that for all three IP3R subtypes, the
enhanced affinity of AdA is not due to its 29-phosphate interacting
more effectively than the 1-phosphate of IP3 with the IBC.
A Bisphosphate Moiety is not Essential for Activation of
IP3 Receptors by AdA
All known active analogues of IP3 have structures equivalent to
its 4,5-bisphosphate moiety [13]. Structures of the IBC with and
without IP3 bound provide a rationale for this requirement by
revealing that these two phosphate groups contact opposite sides
(the a- and b-domains) of the clam-like IBC, closure of which
initiates IP3R activation [4,41]. Substantial evidence suggests that
the 40,30-bisphosphate moiety of AdA mimics the critical 4,5-
bisphosphate of IP3 [8] (Figure 1A).
40-dephospho-AdA at concentrations up to 300 mM failed to
evoke Ca2+ release via any IP3R subtype (Figure 6A). This is
consistent with previous analyses by both functional and binding
assays of IP3R1 [28,46]. 30-dephospho-AdA did, however, cause
detectable Ca2+ release albeit with much reduced potency
(Figure 6B). The synthetic route used to prepare 30-dephospho-
AdA makes it extremely unlikely that the activity could be due to
minor contamination with AdA or related structures with a vicinal
bisphosphate moiety. Maximal attainable concentrations of 30-
dephospho-AdA (300 mM) failed to release the entire IP3-sensitive
Ca2+ store, but comparison of the concentrations required to
achieve the same submaximal Ca2+ release suggests that 30-
dephospho-AdA is ,10,000-fold less potent than AdA at all three
IP3R subtypes. With such a massive reduction in potency the lesser
sensitivity of DT40-IP3R3 cells to AdA means that even the
highest practicable concentration of 30-dephospho-AdA (300 mM)
is close to the threshold for detecting Ca2+ release (Figure 6B).
Figure 3. Trimming the adenosine moiety of AdA reduces potency. (A–F) Effects of imidophostin (A), ribophostin (C) and furanophostin (E)
on Ca2+ release via each of the three IP3R subtypes, and the same analogues compared with AdA (B, D and F). Results are means 6 S.E.M. from 3
independent experiments. (G) A cation-p interaction between the adenine of AdA and R504 within the a-domain of the IBC is proposed to stabilize
AdA binding (left). Closure of the clam-like IBC is proposed to be mediated by interactions between the 30-phosphate of AdA and the a-domain of
the IBC (blue ribbon), and between the 40-phosphate and the b-domain of the IBC (green ribbon). In 30-dephospho AdA, a cation-p interaction
between AdA and the IBC a-domain is proposed to be sufficient to allow some effective closure of the clam. R504 is conserved in all three
mammalian IP3R subtypes (right).
doi:10.1371/journal.pone.0058027.g003
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Figure 4. Hydroxyl groups within the glucose ring of AdA are unimportant. (A–D) Effects of manno-AdA (A) and xylo-AdA (C) on Ca2+
release via each IP3R subtype, and the same analogues compared with AdA (B and D). Results are means 6 S.E.M. from 3 independent experiments.
doi:10.1371/journal.pone.0058027.g004
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The inability of high concentrations of 30-dephospho-AdA to
release the entire IP3-sensitive Ca
2+ store is likely to be due solely
to its reduced affinity rather than reduced efficacy. A concentra-
tion of 30-dephospho-AdA (30 mM) that caused detectable Ca2+
release via IP3R1 (,2165%) had no effect on the sensitivity of the
Ca2+ release evoked by a subsequent addition of IP3. The pEC50
was 7.0060.02 and 7.0460.06 (n = 3) for (1,4,5)IP3 alone and in
the presence of 30-dephospho-AdA, respectively (Figure 6C). A
partial agonist would be expected to shift the sensitivity to higher
concentrations of IP3. These results suggest that 30-dephospho-
AdA is a low-affinity full agonist of IP3R.
These results extend our previous analyses of IP3R1 by
demonstrating that for all IP3R subtypes, the 40-phosphate group
of AdA is essential for activity, whereas the 30-phosphate is
important but not essential. 30-dephospho-AdA is the only known
agonist of IP3R to lack a structure equivalent to the 4,5-
bisphosphate moiety of IP3.
Discussion
AdA is a high-affinity full agonist of IP3R that has been
extensively used to explore the behaviour of IP3R [reviewed in8].
The activity of AdA has been confirmed in many cell types, but
hitherto there has been no assessment of its activity in homogenous
populations of IP3R subtypes. We have demonstrated that AdA is
,10-fold more potent than IP3R at each IP3R subtype (Figure 2,
Tables 1 and 2), and the structural determinants of its high-affinity
interaction with IP3R are similar for all three IP3R subtypes.
Contrary to an earlier suggestion that the 29-phosphate of AdA
mediates its enhanced affinity by forming a stronger interaction
with the IBC than the analogous 1-phosphate of IP3, we find that
the 1-phosphate makes a greater contribution to IP3 binding than
does the 29-phosphate of AdA (Figure 5) [12]. A more likely
explanation for the enhanced affinity of AdA is a cation-p
interaction between its adenine moiety and R504 within the a-
subunit of the IBC (Figure 3G) [28]. That explanation is supported
by results for each IP3R subtype showing that truncation of the
adenosine moiety of AdA brings the potency of the resulting
analogues (imidophostin, ribophostin and furanophostin) close to
that of IP3 (Figure 3).
A key step in the initial activation of IP3R by IP3 appears to be
closure of its clam-like IBC as the 4-phosphate of IP3 contacts one
side of the clam (its b-domain) and the 5-phosphate contacts the
other side (a-domain) [4]. That mechanism provides a satisfying
explanation for the long-standing observation that all inositol
phosphates that activate IP3R share this essential 4,5-bisphosphate
moiety. AdA is different in that its 40-phosphate (analogous to the
4-phosphate of IP3, Figure 1A) is essential, but 30-dephospho-AdA
retains activity at all three IP3R subtypes, albeit with very low
affinity (Figure 6). We suggest that for AdA, the need for the
bisphosphate moiety to cause closure of the IBC can be partially
replaced for all IP3R subtypes by having an interaction between
the adenine of AdA and the a-domain substitute for the interaction
between the 30-phosphate (analogous to the 5-phosphate of IP3)
and the a-domain [28]. Finally, whereas the 6-OH and, to a lesser
extent, the 3-OH of IP3 are important for IP3 binding, the
equivalent structures within AdA play lesser roles.
Figure 5. The 29-phosphate of AdA is not the primary cause of
its increased potency. (A) Effects of 29-dephospho AdA on Ca2+
release via each IP3R subtype. (B) The same analogue compared with
AdA. Results are means 6 S.E.M. from 3–4 independent experiments.
doi:10.1371/journal.pone.0058027.g005
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Both store-operated Ca2+ entry, which is triggered by depletion
of IP3-sensitive Ca
2+ stores [47], and the spatial organization of
subcellular Ca2+ signals have been reported to be differentially
affected by IP3, AdA or its analogues [14,16,17,19,21,22]. Our
present results, which demonstrate that AdA structure-activity
relationships are similar for all IP3R subtypes, suggest that
different physiological effects of IP3, AdA or its analogues are
more likely to result from differences in their affinities, kinetics or
rates of degradation than from selective interactions with different
IP3R subtypes.
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